Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.48 · Revenue $75.12M · 2 analysts
Est. EPS $-1.01 · Revenue $121.53M · 2 analysts
Est. EPS $-0.88 · Revenue $130.61M · 1 analysts
Est. EPS $-1.13 · Revenue $150.11M · 1 analysts
EPS $-0.93 · Revenue $129.46M
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $129.5M | +0.5% | 0.0% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-30.8M | +20.5% | 0.0% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +31.4% | +0.3% | 0.0% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -1.0% | +92.7% | 0.0% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -23.8% | +20.8% | 0.0% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $6.2M | +145.7% | 0.0% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +4.8% | +145.5% | 0.0% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | -1004.1% | -110.3% | -147.2% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 3.49x | +23.0% | 0.0% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $232.2M | -3.0% | 0.0% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.93 vs -1.33 | +30.1% | -0.19 vs -0.23 | +18.3% |
| Revenue Surprise | $129.5M vs $127.8M | +1.3% | $34.2M vs $31.6M | +8.0% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Kiper Christopher S | director, 10 percent owner: | Common Stock | A | 25,907 | — |
| Jun 4, 2026 | OBUS NELSON | director | Common Stock | A | 25,907 | — |
| Jun 4, 2026 | Aryeh Jason | director | Common Stock | A | 25,907 | — |
| Jun 4, 2026 | Schechter Joshua | director | Common Stock | A | 25,907 | — |
| Jun 4, 2026 | Korenberg Matthew E | director | Common Stock | A | 25,907 | — |
Operator: Good morning, and thank you for joining Lifecore earnings call for the second quarter and 6 months ended June 30, 2026. [Operator Instructions] Now I'd like to turn the call over to Stephanie Diaz, Manager of Investor Relations for Lifecore. Stephanie Diaz: Good morning, and thank you for joining us. Today, Lifecore Biomedical will provide its earnings results for the second quarter and 6 months ended June 30, 2026, and a corporate update. As the company has recently changed its fiscal year end to align with the calendar year, we will be comparing our results for the second quarter ended June 30, 2026, with the comparable prior year quarter ended May 25, 2025. For the 6-month period, we will be comparing our results from January 1 through June 30, 2026, with the prior year period from November 24, 2024, through May 25, 2025. Hosting the call today from Lifecore are Paul Josephs, President and Chief Executive Officer; and Ryan Lake, Chief Financial Officer. Before we begin, I'd like to remind everyone that today's conference call will contain forward-looking statements. It is important to note that the forward-looking statements made during this call reflect management's judgment and analysis only as of today, August 5, 2026, and the company's actual results could differ materially from those projected in such forward-looking statements. For a more thorough discussion of the risks and uncertainties associated with any forward-looking statements, please see the disclaimer regarding forward-looking statements that is included in our earnings press release, which was furnished to the Securities and Exchange Commission this morning on Form 8-K and is available on our corporate website at lifecore.com as well as our other filings with the Securities and Exchange Commission, including, but not limited, to the company's Form 10-Q for Q2 2026, which was filed with the SEC this morning and is also available on our website. In addition, our earnings press release includes a discussion of and during this call, we will reference certain non-GAAP financial information. You can find relevant non-GAAP reconciliations in our press release. With that, I'd like to turn the call over to Paul Josephs, President and Chief Executive Officer. Paul Josephs: Thank you, Stephanie. Good morning, everyone, and thank you for joining us today. During the second quarter, Lifecore continued to execute with focus and discipline against the strategic objectives we implemented over the last 24 months. We are energized by the success and progress we are making in achieving the 3 pillars of our growth strategy. As a reminder, these pillars are maximizing our existing commercial business, advancing our development pipeline towards commercialization and adding high-quality new programs to our pipeline through business development. This is a thoughtful and deliberate strategy that is designed to drive durable growth over the medium to long term and create value for our …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Paul Josephs | President, Chief Executive Officer & Director | USD 782,079 | Male | 1966 | Active |
Ryan D. Lake | Executive Vice President & Chief Financial Officer | USD 604,940 | Male | 1977 | Active |
Thomas Salus | Chief Legal and Administration Officer & Corporate Secretary | USD 573,284 | Male | 1970 | Active |
Parker K. Javid | Vice President | USD 321,908 | Male | 1969 | Active |
Aaron Perlitsh | Director of Internal Audit & Chief Compliance Officer | — | Male | — | Active |
Jackie Q. Klecker | Executive Vice President of Quality & Development Services | — | Female | — | Active |
Thomas Guldager | Senior Vice President of Operations | — | Male | — | Active |
Mark DaFonseca | Chief Commercial Officer | — | Male | — | Active |
CHASKA, Minn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the CPHI Global Conference.
-- Significant New Program Positioned to Become One of Lifecore's Largest Contracts -- -- Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Drug Product -- -- Program Expected to Contribute to 2028 Commercial Revenues -- CHASKA, Minn., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced it has signed a new agreement to transfer a commercially marketed product to the company's pipeline.
Lifecore Biomedical, Inc. (LFCR) Q2 2026 Earnings Call Transcript
-- Reaffirms 2026 Guidance -- -- Multiple New Business Wins, Adding Impactful Programs to Pipeline -- -- Cost Reduction and Productivity Enhancements Continue to Strengthen Organization -- Conference Call Today at 8:00am ET CHASKA, Minn., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced results for the second quarter and six months ended June 30, 2026.
CHASKA, Minn., July 29, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, before the market opens.
